Thursday, December 8, 2016
The National Institute on Alcohol Abuse and Alcoholism, part of the NIH, is once again challenging the biotech community to design a wearable device capable of measuring blood alcohol in near real-time. The ideal device would be capable of measuring alcohol concentration in the blood or interstitial fluid that surrounds the body’s cells, which differs from existing technology that detects alcohol released through the skin in sweat or vapor. The creators of the winning prototype will be awarded $200,000 and second place will receive $100,000 through Challenge.gov, which lists federal incentive prizes and competitions.
Charles River Laboratories International has launched a full, end-to-end service offering of CRISPR/Cas9 genome engineering technology. Through a licensing arrangement with the Broad Institute of MIT and Harvard, Charles River can now offer custom in vivo and in vitrogenome editing. With this technology, Charles River will be able to develop more translational research models that will ultimately improve the efficiency and effectiveness of the drug discovery process.
Center Point Clinical Services, creator of the Clinical Trial Research Pharmacist (CTRP) solution, has launched the world’s first site-less technology CRO. The site-less CRO model is designed to support the evolving world of clinical trials by empowering study sponsors to de-risk the clinical trial process, increase quality, reduce costs and ensure robust data for regulatory submissions.
Almac Clinical Technologies, part of the Almac Group, a privately held contract pharmaceutical development and manufacturing organization, has announced the formation of a strategic partnership with inVentiv Health, a biopharma outsourcing company combining a leading CRO and the industry’s only contract commercial organization (CCO). The partnership presents an opportunity for both organizations to provide clients and sites with streamlined access to best-in-class clinical trial Interactive Response Technology (IRT) solutions.
Remedy Pharmaceuticals, a privately-held phase III-ready pharmaceutical company focused on bringing a life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, has announced that David Epstein has joined as special advisor to the company’s board of directors.
City of Hope, an independent research and cancer and diabetes treatment center, and Translational Genomics Research Institute (TGen), a biomedical research institute, have formed an alliance to make precision medicine a reality for patients.
Intellia Therapeutics, a genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, has announced the move to its new laboratory facilities at 40 Erie Street, in Cambridge.
Clinical Research IO (CRIO), a Cambridge-based technology company that has developed the first e-source system for clinical research sites, will participate in a new eConnect Partner program with Medidata to eliminate redundant and costly data entry.
NeuroCog Trials, a cognitive services provider for the clinical trials industry, has announced that it is significantly expanding its presence at its headquarters in Durham. Construction is currently underway to give NeuroCog Trials the entire third floor, in addition to their fourth floor space of the SouthCourt building, totaling approximately 22,500 square feet of workspace.